Production (Stage)
Veracyte, Inc.
VCYT
$27.16
-$0.24-0.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.42% | 23.46% | 23.95% | 21.59% | 20.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.42% | 23.46% | 23.95% | 21.59% | 20.66% |
| Cost of Revenue | 15.96% | 8.27% | 4.26% | 0.43% | 1.08% |
| Gross Profit | 26.84% | 31.57% | 34.97% | 34.00% | 32.44% |
| SG&A Expenses | 8.95% | 8.63% | 11.69% | 5.94% | 7.67% |
| Depreciation & Amortization | -23.77% | -27.81% | -25.71% | -17.99% | -10.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.81% | 12.05% | 14.47% | 10.37% | 12.01% |
| Operating Income | 368.89% | 219.23% | 151.07% | 103.06% | 64.57% |
| Income Before Tax | 149.81% | 133.60% | 83.52% | -91.02% | -134.34% |
| Income Tax Expenses | 190.19% | 172.74% | 193.32% | -299.47% | -1,755.88% |
| Earnings from Continuing Operations | 148.48% | 132.44% | 81.45% | -85.96% | -125.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 148.48% | 132.44% | 81.45% | -85.96% | -125.83% |
| EBIT | 368.89% | 219.23% | 151.07% | 103.06% | 64.57% |
| EBITDA | 315.85% | 376.84% | 332.75% | 527.25% | 249.45% |
| EPS Basic | 145.78% | 130.60% | 79.63% | -84.47% | -122.15% |
| Normalized Basic EPS | 1,534.39% | 432.76% | 276.24% | 147.19% | 89.95% |
| EPS Diluted | 143.67% | 128.80% | 78.16% | -84.61% | -123.89% |
| Normalized Diluted EPS | 1,505.93% | 426.50% | 273.68% | 146.98% | 89.95% |
| Average Basic Shares Outstanding | 5.47% | 5.28% | 4.19% | 3.15% | 2.09% |
| Average Diluted Shares Outstanding | 7.65% | 6.79% | 4.91% | 3.37% | 2.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |